$ADTX News

Last published 5mo ago

5mo agoADTXAditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 MillionBusiness WireTransaction values Ignite Proteomics at approximately $150 million and is expected to position Ignite as an independent NYSE-listed functional proteomics company, while Aditxt continues as a separate Nasdaq-listed
5mo agoADTXIgnite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy SelectionBusiness WireRegistry expected to pair Ignite's reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for Ignite over the course
5mo agoADTX GMRE XRNAditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to ShareholdersBusiness WireSeasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital
6mo agoADTXAditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026Business WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-27 reverse split of its common stock.
6mo agoADTXDana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer PatientsBusiness WirePeer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite's platform — the only commercially available multiplex assay in the study—demonstrates predictive value for
7mo agoADTX GMRE XRNAditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive OfficerBusiness WireBusch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating
8mo agoADTXAditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy SelectionBusiness WireIgnite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX)
8mo agoADTXAditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026Business WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing
11mo agoADTXAditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National ListingBusiness WireAditxt has filed a preliminary proxy statement seeking shareholder approval for employee stock purchase plan, company name change, and other proposals Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social
1y agoADTXAditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025Business WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its common stock.
1y agoADTXAditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global MarketBusiness WireProspective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a non-invasive alternative to surgical diagnosis for endometriosis Aditxt, Inc. (NASDAQ:ADTX)
1y agoADTXEvofem Announces Voting Results from Special Meeting of StockholdersPR NewswireEvofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its...
1y agoADTXEvofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media PlatformsPR NewswireEvofem Biosciences, Inc. (Evofem) (OTCID: EVFM) today announced the conclusion and exciting impact of its groundbreaking August 2025 "Say Vagina"...
1y agoADTXEvofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder MeetingPR NewswireIn an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) anticipates the approval of the transactions...
1y agoADTXAditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030Business WirePlans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt", or the "Company"), a social innovation
1y agoADTXIllinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed LawPR NewswireOn August 15, 2025, Illinois enacted House Bill 3489, a measure designed to broaden access to contraception for its residents. This legislation...
1y agoADTXFDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and TrichomoniasisPR NewswireEvofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one...
1y agoADTXEvofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business UpdatePR NewswireWomen's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and...
1y agoADTXAditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ InitiativeBusiness WireCrypto.com to Provide Custody Services for Proposed Aditxt Digital Asset Treasury Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating
1y agoADTXEvofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE ConferencePR NewswireEvofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier, will be honored with the Trailblazing Female Founders...
1y agoADTXAditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other DiseasesBusiness WirePlanned IPO Aligns with Aditxt's Acquire, Build and Capitalize (ABC) Monetization Framework Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to
1y agoADTXAditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ETBusiness WireLivestream to Spotlight Aditxt's Autoimmune Innovation and its Vision to Address One of the Fastest Growing Global Health Challenges Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform
1y agoADTXPhexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary MommyPR NewswireOne viral TikTok, 10 million+ views, and a flood of fearless, funny, and unfiltered replies later, a non-hormonal birth control brand — PHEXXI — has...
1y agoADTXAditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech CommercializationBusiness WirePlan Combines Bitcoin Treasury Strategy and Equity Line to Support 2026 Potential Monetization Events, Starting with Pearsanta's Planned IPO Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a
1y agoADTXAditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ETBusiness WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be
1y agoADTXNotable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual MeetingPR NewswireWomen's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for...
1y agoADTX WINTEvofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of DirectorsBusiness WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc.
1y agoADTXSaundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6Business WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt"), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow's Aditxt Weekly Update by Dr.
1y agoADTX EVFMAditxt Announces Termination of Arrangement Agreement With Appili TherapeuticsBusiness WireWill eliminate approximately $16M in closing obligations Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that it has
1y agoADTXAditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing RequirementsBusiness WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today that it received notification from the Listing Qualifications
1y agoADTX WINTEvofem Reports Fourth Consecutive Year of Net Sales GrowthPR NewswireWomen's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, ...
1y agoADTXEvofem Biosciences Announces Financial Results for the Third Quarter of 2024PR NewswireWomen's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter...
2y agoADTXEvofem Secures Investor Support for Proposed Merger through Voting AgreementsPR NewswireEvofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1...
2y agoADTXEvofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral SolutionPR NewswireAs the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB:...
2y agoADTXEvofem Biosciences Announces Financial Results for the Second Quarter of 2024PR NewswireWomen's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the second quarter...
2y agoADTXAditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBusiness WireAditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the
2y agoADTXAditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBusiness WireAditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced
2y agoADTX EVFMEvofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1stGlobeNewswireSAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy
2y agoADTXEvofem Signs Phexxi® License Agreement for Middle East with Pharma 1PR NewswireWomen's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License ...
2y agoADTX EVFMAditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 ClosingBusiness WireEvofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising
2y agoADTXLupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSECPR NewswireGlobal pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has divested its...
2y agoADTXHello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's HealthcarePR NewswireWomen's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) today announced a new market partnership with Hello Alpha, a telemedicine company...
2y agoADTXEvofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of MatterPR NewswireEvofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No....
2y agoADTXEvofem Biosciences Announces Financial Results for the First Quarter of 2024PR NewswireThe company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or...
2y agoADTXAditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness WireAditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements
2y agoADTX APLIF TSX:APLIAditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)Business WireAssets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc.
2y agoADTXEvofem Reports $18.2 million of Phexxi Net Product Sales in 2023PR NewswireThe company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc....
2y agoADTXEvofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-CalPR NewswireCommercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate...
2y agoADTXFor Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended PregnancyPR NewswireUse of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy,...
2y agoADTXEvofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023PR NewswireEvofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi®...